Literature DB >> 23735743

HIV/AIDS eradication.

Matthew D Marsden1, Jerome A Zack.   

Abstract

Antiretroviral therapy can inhibit HIV replication in patients and prevent progression to AIDS. However, it is not curative. Here we provide an overview of what antiretroviral drugs do and how the virus persists during therapy in rare reservoirs, such as latently infected CD4+ T cells. We also outline several innovative methods that are currently under development to eradicate HIV from infected individuals. These strategies include gene therapy approaches intended to create an HIV-resistant immune system, and activation/elimination approaches directed towards flushing out latent virus. This latter approach could involve the use of novel chemically synthesized analogs of natural activating agents.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23735743      PMCID： PMC3714230          DOI： 10.1016/j.bmcl.2013.05.032

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  57 in total

1.  Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy.

Authors:  D Finzi; J Blankson; J D Siliciano; J B Margolick; K Chadwick; T Pierson; K Smith; J Lisziewicz; F Lori; C Flexner; T C Quinn; R E Chaisson; E Rosenberg; B Walker; S Gange; J Gallant; R F Siliciano
Journal:  Nat Med       Date:  1999-05       Impact factor: 53.440

2.  HIV latency in the humanized BLT mouse.

Authors:  Matthew D Marsden; Michael Kovochich; Nuttee Suree; Saki Shimizu; Roshni Mehta; Ruth Cortado; Gregory Bristol; Dong Sung An; Jerome A Zack
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

3.  Molecular characterization, reactivation, and depletion of latent HIV.

Authors:  David G Brooks; Dean H Hamer; Philip A Arlen; Lianying Gao; Greg Bristol; Christina M R Kitchen; Edward A Berger; Jerome A Zack
Journal:  Immunity       Date:  2003-09       Impact factor: 31.745

4.  BET bromodomain inhibition as a novel strategy for reactivation of HIV-1.

Authors:  Camellia Banerjee; Nancie Archin; Daniel Michaels; Anna C Belkina; Gerald V Denis; James Bradner; Paola Sebastiani; David M Margolis; Monty Montano
Journal:  J Leukoc Biol       Date:  2012-07-16       Impact factor: 4.962

5.  Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides.

Authors:  Paul Bamborough; Hawa Diallo; Jonathan D Goodacre; Laurie Gordon; Antonia Lewis; Jonathan T Seal; David M Wilson; Michael D Woodrow; Chun-Wa Chung
Journal:  J Med Chem       Date:  2012-01-11       Impact factor: 7.446

6.  RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma.

Authors:  David L DiGiusto; Amrita Krishnan; Lijing Li; Haitang Li; Shirley Li; Anitha Rao; Shu Mi; Priscilla Yam; Sherri Stinson; Michael Kalos; Joseph Alvarnas; Simon F Lacey; Jiing-Kuan Yee; Mingjie Li; Larry Couture; David Hsu; Stephen J Forman; John J Rossi; John A Zaia
Journal:  Sci Transl Med       Date:  2010-06-16       Impact factor: 17.956

7.  Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960.

Authors:  Michael Worobey; Marlea Gemmel; Dirk E Teuwen; Tamara Haselkorn; Kevin Kunstman; Michael Bunce; Jean-Jacques Muyembe; Jean-Marie M Kabongo; Raphaël M Kalengayi; Eric Van Marck; M Thomas P Gilbert; Steven M Wolinsky
Journal:  Nature       Date:  2008-10-02       Impact factor: 49.962

8.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.

Authors:  Nicolas Chomont; Mohamed El-Far; Petronela Ancuta; Lydie Trautmann; Francesco A Procopio; Bader Yassine-Diab; Geneviève Boucher; Mohamed-Rachid Boulassel; Georges Ghattas; Jason M Brenchley; Timothy W Schacker; Brenna J Hill; Daniel C Douek; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sékaly
Journal:  Nat Med       Date:  2009-06-21       Impact factor: 53.440

9.  Generation of HIV latency in humanized BLT mice.

Authors:  Paul W Denton; Rikke Olesen; Shailesh K Choudhary; Nancy M Archin; Angela Wahl; Michael D Swanson; Morgan Chateau; Tomonori Nochi; John F Krisko; Rae Ann Spagnuolo; David M Margolis; J Victor Garcia
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

10.  Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes.

Authors:  H E Gendelman; J M Orenstein; M A Martin; C Ferrua; R Mitra; T Phipps; L A Wahl; H C Lane; A S Fauci; D S Burke
Journal:  J Exp Med       Date:  1988-04-01       Impact factor: 14.307
View more
  22 in total

1.  Experimental Approaches for Eliminating Latent HIV.

Authors:  Matthew D Marsden; Jerome A Zack
Journal:  For Immunopathol Dis Therap       Date:  2015

2.  Comorbidities associated with HIV and antiretroviral therapy (clinical sciences): a workshop report.

Authors:  L T Vernon; Plp Jayashantha; M M Chidzonga; M C Komesu; R G Nair; N W Johnson
Journal:  Oral Dis       Date:  2016-04       Impact factor: 3.511

Review 3.  Studies of retroviral infection in humanized mice.

Authors:  Matthew D Marsden; Jerome A Zack
Journal:  Virology       Date:  2015-02-11       Impact factor: 3.616

Review 4.  Humanized Mouse Models for Human Immunodeficiency Virus Infection.

Authors:  Matthew D Marsden; Jerome A Zack
Journal:  Annu Rev Virol       Date:  2017-07-26       Impact factor: 10.431

5.  Double trouble: HIV latency and CTL escape.

Authors:  Matthew D Marsden; Jerome A Zack
Journal:  Cell Host Microbe       Date:  2015-02-11       Impact factor: 21.023

6.  Neutralizing the HIV reservoir.

Authors:  Matthew D Marsden; Jerome A Zack
Journal:  Cell       Date:  2014-08-28       Impact factor: 41.582

7.  Highly significant antiviral activity of HIV-1 LTR-specific tre-recombinase in humanized mice.

Authors:  Ilona Hauber; Helga Hofmann-Sieber; Jan Chemnitz; Danilo Dubrau; Janet Chusainow; Rolf Stucka; Philip Hartjen; Axel Schambach; Patrick Ziegler; Karl Hackmann; Evelin Schröck; Udo Schumacher; Christoph Lindner; Adam Grundhoff; Christopher Baum; Markus G Manz; Frank Buchholz; Joachim Hauber
Journal:  PLoS Pathog       Date:  2013-09-26       Impact factor: 6.823

8.  Initiation of Antiretroviral Therapy during Primary HIV Infection: Effects on the Latent HIV Reservoir, Including on Analytic Treatment Interruptions.

Authors:  Eva M Shelton; Daniel B Reeves; Rachel A Bender Ignacio
Journal:  AIDS Rev       Date:  2020-10-26       Impact factor: 2.500

9.  Prodrugs of PKC modulators show enhanced HIV latency reversal and an expanded therapeutic window.

Authors:  Jack L Sloane; Nancy L Benner; Katherine N Keenan; Xiaoyu Zang; Mohamed S A Soliman; Xiaomeng Wu; Melanie Dimapasoc; Tae-Wook Chun; Matthew D Marsden; Jerome A Zack; Paul A Wender
Journal:  Proc Natl Acad Sci U S A       Date:  2020-05-05       Impact factor: 11.205

Review 10.  Study of viral pathogenesis in humanized mice.

Authors:  Jenna M Gaska; Alexander Ploss
Journal:  Curr Opin Virol       Date:  2015-01-22       Impact factor: 7.090
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.